Devonian Health Group Inc. (TSXV:GSD)
Canada · Delayed Price · Currency is CAD 7.75
-0.75 (-8.82%)
Aug 7, 2026, 2:32 PM EST
Devonian Health Group Revenue
Devonian Health Group had revenue of 176.64K CAD in the quarter ending April 30, 2026, a decrease of -97.60%. This brings the company's revenue in the last twelve months to 1.72M, down -94.71% year-over-year. In the fiscal year ending July 31, 2025, Devonian Health Group had annual revenue of 23.59M with 22.19% growth.
Revenue (ttm)
1.72M
Revenue Growth
-94.71%
P/S Ratio
7.20
Revenue / Employee
299.53K
Employees
11
Market Cap
21.55M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jul 31, 2025 | 23.59M | 4.28M | 22.19% |
| Jul 31, 2024 | 19.31M | 16.96M | 723.15% |
| Jul 31, 2023 | 2.35M | 40.20K | 1.74% |
| Jul 31, 2022 | 2.31M | 830.50K | 56.32% |
| Jul 31, 2021 | 1.47M | -668.47K | -31.19% |
| Jul 31, 2020 | 2.14M | -1.86M | -46.49% |
| Jul 31, 2019 | 4.00M | 837.05K | 26.42% |
| Jul 31, 2018 | 3.17M | - | - |
| Jul 31, 2017 | - | - | - |
| Jul 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Devonian Health Group News
- 13 days ago - Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering - PRNewsWire
- 20 days ago - Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Years - PRNewsWire
- 5 weeks ago - Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026 - PRNewsWire
- 4 months ago - Devonian Reports Results of its Annual General and Special Meeting of Shareholders - PRNewsWire
- 4 months ago - Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026 - PRNewsWire
- 6 months ago - Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects - PRNewsWire
- 6 months ago - Devonian Advances Thykamine™ Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls - PRNewsWire
- 6 months ago - Devonian reports additional molecular data from MASH liver study - PRNewsWire